Global Biopharma Company Signs Agreement to Use OmniComm Systems Tech Suite


Applied Clinical Trials

OmniComm Systems, Inc. continues to expand its role in the rare disease treatment area with a new agreement. An international biopharmaceutical company has signed a five-year contract to use OmniComm’s suite of eClinical solutions to build and manage global Phase III and Phase IV studies targeting rare pediatric diseases. 

For more information, click here. 

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.